Evidence map›Paper›PMID 42761679›Full record

ArticleCureus2026

Recurrent Epistaxis as a Rare Presentation of Extramedullary Multiple Myeloma.

Vinay Kumar, Vinita Paswan, Prachi Kumar, Rahul Bhargava

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vinay KumarOtolaryngology-Head and Neck Surgery, Mahamaya Rajkiya Allopathic Medical College, Akbarpur, IND.
Vinita PaswanPathology and Laboratory Medicine, All India Institute of Medical Sciences (AIIMS), Raebareli, IND.
Prachi KumarHistopathology, Yashoda Medicity, Ghaziabad, IND.
Rahul BhargavaOphthalmology, GS Medical College & Hospital, Pilkhuwa, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extramedullary multiple myeloma is characterized by clonal plasma cell proliferation outside the bone marrow and is associated with an adverse prognosis, particularly when accompanied by high-risk cytogenetic abnormalities. Sinonasal involvement is rare and may present with recurrent epistaxis or unilateral nasal obstruction, creating diagnostic overlap with inflammatory, vascular, lymphoid, and epithelial sinonasal lesions. We report a 54-year-old man with an eight-month history of progressive right-sided nasal obstruction and intermittent epistaxis that became increasingly frequent and refractory to nasal packing. Magnetic resonance imaging showed a right sinonasal mass involving the nasal cavity and maxillary sinus, with septal deviation and no radiological evidence of orbital floor or nasal septal erosion. Endoscopically guided biopsy demonstrated a dense plasma cell infiltrate with mature and atypical forms. Systemic evaluation revealed anemia, multiple lytic skull and humeral lesions, 32% bone marrow plasma cell infiltration, an IgG monoclonal protein with lambda light-chain restriction, and high-risk cytogenetic abnormalities including CKS1B 1q gain, deletion 17p, and deletion 13q. These findings established a diagnosis of high-risk symptomatic multiple myeloma with extramedullary sinonasal involvement rather than a solitary extramedullary plasmacytoma. This case emphasizes that recurrent epistaxis associated with a unilateral sinonasal mass warrants early biopsy and systemic evaluation, particularly when clinical or laboratory features suggest an underlying plasma cell neoplasm.

Indexed as

epistaxisextramedullary diseaselytic bone lesionsmultiple myelomaplasma cell neoplasmsinonasal mass

Identifiers

PMID42761679
PMCPMC13588276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.